Drug Trial News

RSS

Moderate strengthening exercises may slow progression of Lou Gehrig's disease

Moderate strengthening exercises may help people with early stage ALS maintain function and quality of life longer, according to a study published in the June 5, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

5 Jun 2007

Do pay-for-performance incentives improve quality of care?

Pay-for-performance incentives have been proposed as a method to improve the quality of care received by patients.

5 Jun 2007

After epilepsy surgery, quality of life related more to seizures than memory

Epilepsy surgery can eliminate seizures for 60 to 85 percent of people with temporal lobe epilepsy who do not respond well to medications.

5 Jun 2007

VEGF Trap (aflibercept) shows activity in patients with advanced ovarian cancer

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

5 Jun 2007

Vorinostat shows anti-cancer activity in recurrent gliomas

North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme.

5 Jun 2007

Study finds lymphoma drug effective over long term

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.

5 Jun 2007

Circulating tumor cells predict how prostate cancer patients do with chemotherapy

The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.

5 Jun 2007

Treatment for early prostate cancer associated with type of specialist seen

A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.

5 Jun 2007

$Transplantation does not benefit patients with refractory myeloma$

Transplantation does not benefit patients with refractory myeloma

A study, led by Dr. Joan Blad, researcher of the Haematooncology Group of Hospital Cl'nic-IDIBAPS (Barcelona), in collaboration with Dr. Laura Rosi'ol, researcher of the same group, assessed the efficiency in terms of response and survival of autologous bone marrow transplantation in patients suffering from refractory myeloma previously having undergone high-dose chemotherapy (HDT).

5 Jun 2007

Chromium picolinate and biotin combo improves blood sugar control in people with type 2 diabetes

Nutrition 21, Inc. (NASDAQ: NXXI) today announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).

5 Jun 2007

Study finds difference in survival rates among white and black women with advanced breast cancer

Despite modest overall improvements in breast cancer survival rates for women with advanced disease over the last two decades, the rates for black women have not improved and the difference in life expectancy between white and black women continues to widen, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Jun 2007

Revlimid may change the way physicians treat multiple myeloma

Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.

5 Jun 2007

Arsenic trioxide shows survival benefit for leukemia patients

Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide ,marketed as Trisenox, significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.

5 Jun 2007

Bone-targeting radioisotope radium-223 for prostate cancer treatment

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).

5 Jun 2007

Protein S-100 linked to melanoma recurrence

Higher levels of a protein called S-100 in patients with melanoma may correlate with a higher risk of having the disease return, say researchers at the University of Pittsburgh Cancer Institute (UPCI), who presented their findings today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007

78 percent of living right liver donors experienced post-operative complications

More than 78 percent of living right liver donors experienced post-operative complications, according to a new study that uses a replicable complication classification system. Most of the complications were minor, though some were more serious.

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

PET plus CT - best test for ovarian cancer

An advanced molecular imaging technique influenced the management of women with ovarian cancer, detected more sites of disease and identified women whose disease was likely to progress, according to an Australian study released during the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

5 Jun 2007

PET/CT best for monitoring Crohn's disease

The molecular imaging power of PET/CT is invaluable in noninvasively monitoring Crohn's disease,a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people, according to a study released by Belgian scientists at the 54th Annual Meeting of SNM.

5 Jun 2007

PET accurately identifies esophageal cancer patients' positive responses to chemotherapy

Early metabolic imaging with positron emission tomography (PET) accurately identifies patients responding to chemotherapy for esophageal cancer, noted German researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

5 Jun 2007